Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite

Ozempic Won’t Sink This Medical Device Stock’s Prospects — Quite the Opposite

Anti-obesity drugs rose in popularity last year, helping the leaders in this market — notably Eli Lilly and Novo Nordisk — crush the market. However, some medical device specialists got the wrong end of the stick. That was the case with Abbott Laboratories (NYSE: ABT), whose diabetes care segment is perceived as its most important growth driver. Some investors thought GLP-1 medicines such as Ozempic could decrease demand for some of Abbott’s key products.

But that’s not the case. Anti-obesity medicines won’t harm Abbott Laboratories’ business. In fact, the opposite could be true. Let’s find out why.

Complementary ways to help diabetics

Last year, Abbott’s sales of $40.1 billion fell 8.1% year over year. The decline was due to a drop in demand for COVID-19 diagnostic products. Putting that segment aside, Abbott’s top line increased by 11.6%. But even that pales in comparison to the company’s continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. In 2023, FreeStyle Libre sales jumped by 23.2% year over year to $5.3 billion.

Could Ozempic and competing weight-loss therapies lead to reduced demand for Abbott Laboratories’ CGM devices? The numbers tell a different story. Abbott’s management argues that patients often use GLP-1 medicines in combination with CGM solutions. An analysis of pharmacy data Abbott released last year strongly suggests that people on weight-loss therapies have higher rates of CGM adoptions.

DexCom, Abbott’s most important competitor in the CGM market, echoes this sentiment. As DexCom CEO Kevin Sayer recently said: “The data clearly show that CGM usage grows faster in GLP-1 users than those who are not on therapy. This further demonstrates the complementary nature of DexCom CGM across all therapy regimes in diabetes.” In other words, Abbott’s most significant growth driver is safe, at least for now. It doesn’t look like GLP-1 drugs will make its CGM devices obsolete. Quite the contrary.

Here’s another important point: The CGM market has a massive worldwide opportunity. More than half a billion adults now have diabetes, but only about 1% of them use this technology. True, many of them are in developing countries where Abbott Laboratories has yet to launch its FreeStyle Libre franchise. However, the potential is there, and few are better positioned than this medical device giant to pounce on it.

Picking up after Ozempic

Weight-loss therapies like Ozempic have proved extremely effective in helping patients achieve their goals. However, they lead to people shedding quite a bit of muscle along with fat. That can be a problem — excessive muscle loss can have negative health consequences. Some studies have found that as much as 40% of Ozempic users lose weight from decreased muscle mass.

Abbott is looking to address this issue, too. The company launched Protality, a brand designed to develop products to aid people in their weight loss journey. Abbott’s first launch within this business is a low-calorie protein shake. Getting enough protein is an essential part of maintaining muscle mass, and the “low-calorie” part of the equation should help patients keep their overall weight down.

In other words, this is a way to help people lose fat and not muscle. It’s too early to tell how successful Abbott’s new Protality brand will be, but it again shows that the rise of Ozempic is hardly a net negative for the company’s business.

Abbott’s prospects remain strong

Abbott Laboratories has an excellent track record of developing innovative medical devices. Even if its FreeStyle Libre franchise were compromised, the smart money would be on the company to find ways around that challenge. It did so during the pandemic. Procedure volume dropped like a rock, but the healthcare giant kept its revenue afloat by quickly becoming a leader in the COVID-19 diagnostic market.

However, it doesn’t look like weight-loss medicines will negatively impact Abbott’s long-term prospects at all. And there are many other reasons to invest in the company, including its streak of 52 consecutive years of dividend increases, making it an excellent income stock. Here’s the bottom line: Abbott Laboratories is still a top pick for long-term investors.

SPONSORED:

Should you invest $1,000 in Abbott Laboratories right now?

Before you buy stock in Abbott Laboratories, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of February 26, 2024

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy.